Immunostimulatory and Immunodynamic Modeling Analysis to Determine a Plausible Starting Dose of mRNA‐4359 for Use in First‐In‐Human Trials

ABSTRACT The investigational antigen‐specific immunotherapy mRNA‐4359 is a lipid nanoparticle–encapsulated mRNA‐based immunotherapy that encodes for the immunogenic indoleamine 2,3‐dioxygenase (IDO) and programmed death‐ligand 1 (PD‐L1) antigens. An ongoing first‐in‐human (FIH) phase 1/2 clinical tr...

Cur síos iomlán

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Stephen A. Greene, Madhav Channavazzala, Bhairav Paleja, Harshbir Singh Sandhu, Rukmini Kumar, Husain Attarwala, Linh Van, Min Liang
Formáid:	Artigo
Teanga:	Inglês
Foilsithe / Cruthaithe:	Wiley 2026-02-01
Sraith:	CPT: Pharmacometrics & Systems Pharmacology
Ábhair:	antigens cancers dose response immunology model based drug development modeling
Rochtain ar líne:	https://doi.org/10.1002/psp4.70188
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Immunostimulatory and Immunodynamic Modeling Analysis to Determine a Plausible Starting Dose of mRNA‐4359 for Use in First‐In‐Human Trials

Míreanna comhchosúla